Navigation Links
Fenwal Receives FDA Clearance for Wireless Data Export on ALYX Blood-Collection System
Date:12/16/2010

LAKE ZURICH, Ill., Dec. 16, 2010 /PRNewswire/ -- Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market its ALYX™ component collection system with new wireless data export capabilities.

The ALYX system is a mobile blood component collection device used primarily to collect red blood cells.  The system can collect two units of red cells from a single donor in less than 30 minutes.  

The addition of wireless data export allows blood collection professionals to electronically access detailed information about donation procedures on mobile and fixed-site blood drives.  These data can then be used to track and improve blood center performance and enhance the donation experience for donors and collectors.

When accompanied by the Fenwal data exchange system, scheduled for release in the first half of 2011, data export will allow centers to create customized reports with procedure and other data from the ALYX system.  Blood centers can use these data to identify training opportunities designed to enhance operator and system performance.

Fenwal is unique in offering data export capabilities designed for open-source compatibility with blood and plasma center information systems.  Earlier this year Fenwal received FDA clearance for wireless data export on the Fenwal AMICUS™ system, which is used to collect platelets, and the Fenwal AUTOPHERESIS-C™ system, which collects plasma.  

"In providing data export for apheresis systems, our objective is to help the professionals who collect blood and plasma to improve how they work, optimizing their productivity and offering a positive experience for donors," said William H. Cork, chief technology officer for Fenwal.  "Blood collectors are vital to the nation's blood supply and Fenwal is dedicated to supporting their mission.  Since ALYX is a mobile collection system used in many different settings outside blood centers, wireless capability is helpful to transmit information about mobile collection, allowing centers to gain new insight into their efficiency on mobile blood drives."  

About Fenwal

Fenwal, Inc. (www.fenwalinc.com) is a global medical technology company focused on improving blood collection, filtration, separation, storage and transfusion to ensure the availability, safety and effectiveness of blood components.  Fenwal is unique in the depth of its experience and commitment to transfusion medicine.  The company offers the broadest range of products for the automated and manual collection of blood and blood components.  Fenwal became an independent company in 2007, but its roots go back to 1949 with the founding of Fenwal Laboratories.  Fenwal developed the first flexible, single-use container for blood collection, eliminating complications associated with glass containers and allowing blood to be separated into therapeutic components.  Today, the company's products and advanced collection and separation technologies are used to help treat patients on six continents.  Fenwal, Inc. is based in Lake Zurich, Illinois.


'/>"/>
SOURCE Fenwal, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. William Cork Joins Fenwal as Chief Technology Officer
2. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
3. Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets
4. FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
5. Fenwal Receives FDA Clearance for Amicus(R) Separator With Wireless Connectivity
6. Appellate Court Decides in Favor of Fenwal
7. FDA Clears Software Upgrade for Fenwal Plasma-Collection System
8. Fenwal Named Exclusive Provider of AccuVeins Award-Winning Vein Illumination Device for Blood and Plasma Centers
9. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
10. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
Breaking Medicine News(10 mins):